New Treatments Target the Inflammation Driving Bronchiectasis Lung Damage
A clinical review maps the inflammatory pathways destroying airways in bronchiectasis and spotlights emerging targeted therapies offering new hope.
Summary
Bronchiectasis is a chronic lung disease where impaired mucus clearance, recurrent infection, and persistent inflammation create a destructive cycle of progressive airway damage. This review from Mayo Clinic and UT Southwestern synthesizes the key inflammatory patterns driving disease — primarily neutrophilic but also eosinophilic — alongside biomarkers and treatment options. Notably, reversible dipeptidyl peptidase-1 (DPP-1) inhibitors show promise in dampening neutrophil-driven damage, while patients with eosinophilic bronchiectasis may respond to biologics targeting type 2 inflammation. The authors frame inflammation as the central therapeutic target, emphasizing personalized, endotype-driven care for improved patient outcomes.
Detailed Summary
Bronchiectasis is a chronic, often underappreciated airway disease in which permanently dilated and damaged bronchi become trapped in a self-perpetuating cycle of mucus stasis, infection, and inflammation. Despite its growing global prevalence and significant morbidity, targeted anti-inflammatory treatments have historically lagged behind those developed for related conditions like asthma or COPD.
This clinical review, authored by pulmonologists from Mayo Clinic and UT Southwestern, consolidates current understanding of the inflammatory mechanisms underpinning non-cystic fibrosis bronchiectasis in adults. The authors organize inflammation into distinct but overlapping endotypes to guide clinicians toward more precision-oriented management.
Neutrophilic inflammation is identified as the dominant driver of bronchiectasis, with neutrophil serine proteases causing direct tissue destruction. Reversible DPP-1 inhibitors — which block protease activation during neutrophil maturation — represent a promising pharmacological advance in this space. Separately, an eosinophilic endotype has emerged as clinically meaningful, with evidence supporting glucocorticoid use and biologic therapies targeting type 2 cytokine pathways in eligible patients.
Beyond these primary endotypes, the review discusses impaired epithelial barrier function, mucociliary abnormalities, immune dysregulation, and inflammation triggered by infections, environmental exposures, and autoimmune diseases — underscoring the heterogeneous nature of bronchiectasis pathophysiology.
The authors emphasize practical diagnostic evaluation and biomarker-guided endotyping as essential steps toward personalized treatment. A key caveat is that this is a narrative review based solely on existing literature, and the evidence base for several emerging therapies remains early-stage. Nonetheless, the framework provided offers clinicians a structured approach to a disease where nuanced, individualized care is increasingly achievable.
Key Findings
- Neutrophilic inflammation is the hallmark of bronchiectasis; DPP-1 inhibitors show promise by blocking neutrophil serine protease activation.
- An eosinophilic endotype responds to glucocorticoids and biologics targeting type 2 inflammation pathways.
- Bronchiectasis involves overlapping mechanisms including mucociliary dysfunction, immune dysregulation, and infection-triggered inflammation.
- Biomarker-guided endotyping is essential for personalized, precision treatment strategies in bronchiectasis.
- Targeted anti-inflammatory therapies have historically been limited but are now an active area of clinical development.
Methodology
This is a narrative clinical review, not an original research study. It synthesizes existing literature on inflammatory mechanisms, biomarkers, and treatments in non-cystic fibrosis bronchiectasis in adults. The review was written to be accessible to general clinicians.
Study Limitations
As a narrative review, this paper is subject to selection bias in the literature cited and does not provide systematic meta-analytic conclusions. Evidence for several emerging therapies remains preliminary, with limited large-scale randomized trial data. The review focuses on non-cystic fibrosis bronchiectasis in adults, limiting generalizability to pediatric or CF populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.